The treatment options available for patients with hepatocellular carcinoma (HCC) with portal vein invasion (PVI) include sorafenib, transarterial radioembolization (TARE), radiation therapy (RT), transarterial chemoembolization with RT, and proton beam irradiation. Herein, we present a case of HCC with segmental PVI that was managed via TARE. The patient had a 4 cm HCC that invaded the segment VIII portal vein branch without extrahepatic spread. Liver function was Child-Pugh grade A, and performance status was good. TARE was performed without any adverse events, and a radiological complete response (CR) was achieved. Thereafter, the patient was followed-up every 3-6 months without any further treatment, and the CR was maintained for >3 years. Therefore, TARE may be a useful alternative therapeutic option for patients with HCC exhibiting segmental PVI. (J Liver Cancer 2019;19:159-164) 
IntroductIon
Hepatocellular carcinoma (HCC) with portal vein invasion (PVI) is classified as an advanced stage tumor according to the Barcelona Clinic Liver Cancer (BCLC) staging system; sorafenib is the first-line therapeutic option for patients with this disease. 1 However, sorafenib resulted in only a modest survival benefit compared to placebos in such HCC patients. [2] [3] [4] Alternative therapeutic options include transarterial radioembolization (TARE), stereotactic body radiation therapy (RT), transarterial chemoembolization (TACE) plus RT, and proton beam irradiation; all have been used to treat pa-tients with advanced HCC without extrahepatic metastases.
In a recent study, TACE plus RT exhibited a significant survival benefit compared with sorafenib for patients with advanced HCC accompanied by macroscopic vascular invasion. 5 However, the current practice guidelines indicate that patients with advanced HCC accompanied by macroscopic vascular invasion are contra-indicated for TACE because of the high risks of post-embolization syndrome and hepatic insufficiency. [6] [7] [8] Accordingly, TARE is a useful option for patients with HCC with PVI; TARE is associated with a longer time to progression, a lower incidence of post-embolization syndrome, and a shorter hospitalization than those observed after TACE. [9] [10] [11] [12] Herein, we report a case of HCC with segmental PVI that was successfully managed with TARE. 
Imaging findings

Diagnosis and treatment
On the basis of the clinical and imaging findings, the patient was diagnosed with a 4-cm HCC invading the segment VIII portal vein branch without any extrahepatic spread. He had a preserved liver function (Child-Pugh score of 5) and a performance status score of 0. Therefore, the HCC was classified as an advanced stage tumor by using the BCLC staging system, and as a stage III (T3, N0, M0) tumor according to the modified International Union Against Cancer system. We decided to perform TARE using the radioisotope yttrium 90 ( 90 Y). Hepatic angiography and 99m technecium-macroaggregated albumin ( 99m Tc-MAA) nuclear scan were performed as pretreatment simulation tests. Hepatic angiography revealed a hypervascular tumor in segments VII/VIII but without any anatomical variation of the hepatic arterial system ( Fig. 3 ). On the 99m Tc-MAA nuclear scan, the lung shunt fraction was 5%; the patient was thus eligible for TARE without any dose reduction. TARE was performed by using Th-eraSphere ® glass microspheres (BTG, London, UK); the total infused radiation activity was 3.95 GBq. The dose was calcu- the initial tumor response evaluation, and radiological CR was maintained for >3 years (Fig. 4) . 
C D A B
https://www.e-jlc.org/ high serum AFP level (≥1,000 ng/mL) is a major predictor of poor survival after surgical resection in patients with HCC. 16 Therefore, we considered locoregional therapy such as TARE or TACE plus RT as the initial treatment. On the basis of the PVI status of the patient, we selected TARE rather than TACE plus RT because TARE is associated with a lower risk of post-embolization syndrome than TACE is. 9, 10 TARE is an intra-arterial therapy using 90 Y-labeled microspheres (TheraSphere ® or SIR-Spheres [Sirtex Medical, North Sydney, Australia]); the radiation induces extensive tumor necrosis. This therapy is increasingly used to treat HCC, especially in Western countries. 17 Although there is no consensus regarding the optimal use of TARE, TARE is primarily considered for patients with locally advanced HCC and good liver function. 9 In conclusion, we described a case of a single HCC with segmental PVI that was successfully managed with TARE.
Thus, TARE may be a useful alternative treatment option for patients with locally advanced HCC. 
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